Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 14/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21513454 | 0.88 | OPRK1 (0.36) | OPRK1SLC22A12JAK2JAK1HRH4 | |
| SCHEMBL26131948 | 0.86 | OPRK1 (0.36) | OPRK1JAK1 | |
| SCHEMBL29968141 | 0.86 | OPRK1 (0.36) | OPRK1JAK1 | |
| SCHEMBL26590484 | 0.84 | OPRK1 (0.36) | OPRK1HTR3AHRH4 | |
| SCHEMBL29968894 | 0.83 | OPRK1 (0.38) | OPRK1 | |
| SCHEMBL26132097 | 0.83 | OPRK1 (0.38) | OPRK1 | |
| SCHEMBL29969608 | 0.82 | OPRK1 (0.43) | OPRK1JAK2JAK1HRH4 | |
| SCHEMBL26131525 | 0.82 | OPRK1 (0.43) | OPRK1JAK2JAK1HRH4 | |
| SCHEMBL29969075 | 0.81 | JAK2 (0.36) | OPRK1JAK2HRH4 | |
| SCHEMBL26131704 | 0.81 | JAK2 (0.36) | OPRK1JAK2HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |